Millions of breast cancer patients could avoid chemotherapy with new genome test
A new genomic test could allow millions of breast cancer patients to avoid chemotherapy. The test identifies which patients are unlikely to benefit from chemotherapy, thus sparing them from its side effects. Clinical trials have shown that patients who do not receive chemotherapy have similar outcomes to those who do.
- ▪The genomic test, called Prosigna, measures gene activity related to breast cancer growth.
- ▪In a trial, over 4,400 participants were assessed to determine their need for chemotherapy after surgery.
- ▪Results indicated that 94.8% of patients receiving chemotherapy were alive and free from recurrence, compared to 93.6% of those who did not receive it.
Opening excerpt (first ~120 words) tap to expand
NewsHealthMillions of breast cancer patients could avoid chemotherapy with new genome testDoctors said the test shows people with certain forms of the disease can safely avoid chemotherapyNicole Wootton-Cane Friday 29 May 2026 23:25 BSTBookmarkCommentsGo to commentsBookmark popoverRemoved from bookmarksClose popover{"translations":{"comments":"Go to comments","share":"Share","copyLink":"Copy link","bookmark":"Bookmark","removeBookmark":"Remove bookmark"},"showComments":true,"showBookmark":true,"articleId":"b2986269","articleMeta":{"url":"https://www.independent.co.uk/news/health/breast-cancer-chemotherapy-genome-test-b2986269.html","title":"Millions of breast cancer patients could avoid chemotherapy with new genome test"}}Coronation Street legend reveals breast cancer diagnosisYour…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Independent.
Discussion
0 commentsMore from The Independent
